New immunisation reference page: Moderna COVID-19 vaccine
Following the announcement by the Australian Government that 25 million doses (as well as additional variant specific versions) of Moderna's COVID-19 vaccine, Elasomeran, had been secured for the Australian population, this vaccine was last week granted provisional determination by the TGA.
Our new reference page explores the various clinical trials involving Elasomeran, as well as details the immunogenicity, efficacy and safety data available for this vaccine.
要阅读更多信息，请点击以下链接：
MVEC: Moderna COVID-19 vaccine
MVEC eLearning: Vaccines in Pregnancy
MVEC 很高兴推出我们的下一个电子学习包。我们的电子学习包旨在帮助免疫提供者巩固和评估他们的技术技能。我们提供有针对性的资源来协助我们的电子学习，并且在完成相应的电子学习测验后将提供结业证书。
Vaccines in Pregnancy has been designed to provide an overview of vaccines that are recommended in pregnancy, vaccines that are contraindicated in pregnancy and the process to follow if a contraindicated vaccine is inadvertently administered during pregnancy.
You can access Vaccines in Pregnancy via our MVEC 教育门户 或通过以下链接：
MVEC eLearning: Vaccines in Pregnancy
TGA grants provisional determination for the Moderna COVID-19 vaccine, Elasomeran
The Therapeutic Goods Administration (TGA) has granted provisional determination to Moderna Australia Pty Ltd for their COVID-19 vaccine candidate, Elasomeran. It is being considered for use in those aged 12 years or older for active immunisation to prevent COVID-19 disease. It is an mRNA vaccine requiring two doses, given 28 days apart.
Granting provisional determination means that Moderna Australia Pty Ltd is now eligible to apply for provisional registration. Following the provisional pathway provides a formal and transparent mechanism for speeding up the registration of promising new medicines with preliminary clinical data.
Provisional determination is only granted once the TGA has considered all eligibility criteria, including evidence of a plan to submit comprehensive clinical data.
You can read the press release from the TGA below:
TGA grants provisional determination for the Moderna COVID-19 vaccine, Elasomeran
For more information on the process of COVID-19 vaccine provisional approval please refer to our reference page:
MVEC: Provisional registration of COVID-19 vaccine(s) in Australia
The Conversation: What’s Australia’s first local Pfizer-style COVID vaccine? And when might it be in our arms? An mRNA expert explains
A research team at Monash University are working on developing Australia’s first mRNA vaccine candidate, with phase 1 trials set to begin in October or November this year.
Although the vaccine under development works by the same principles as the Pfizer and Moderna vaccines by using a genetic code called RNA to spark the production of the coronavirus’s specific spike protein, there are key notable differences.
Firstly, the Monash mRNA vaccine directs cells to make a small part of the spike protein, the receptor binding domain. The receptor binding domain is the tip of the spike protein which is the part that is mutating to form new variants of COVID disease. Targeting this part of the spike protein allows variant-specific responses, for which there is a strong clinical need.
Secondly, existing vaccines are modelled on the original strain of the virus first detected in Wuhan, however, the Monash mRNA vaccine has since been changed to sequence the Beta strain – a strain which was first detected in South Africa for which vaccines created from the original variant are less effective.
This highlights the flexibility of mRNA vaccines with sequences being able to be changed and adapted to new variants that have emerged and that may emerge in the future.
Plans are underway for the vaccine to be developed locally, an important step in developing Australia’s capacity for mRNA vaccine production and the newly developing Australian RNA biotechnology sector overall.
要了解更多信息，请点击以下链接：
The Conversation: What’s Australia’s first local Pfizer-style COVID vaccine? And when might it be in our arms? An mRNA expert explains
Healthed Going Viral Podcast featuring A/Prof Nigel Crawford
Associate Professor Nigel Crawford is interviewed by Dr David Lim, GP and Medical Educator on Healthed Australia’s Going Viral podcast. In this podcast, Nigel discusses the clinical features of Thrombosis with thrombocytopenia syndrome (TTS) and provides an approach for diagnosing and managing it.
您可以在这里收听播客：
Healthed Australia: Going Viral Podcast Episode 157: AZ Clots – Are you missing it?
PHN Webinar: Primary care identification and management of thrombosis with thrombocytopenia syndrome (TTS)
The PHN will be hosting a webinar for GPs on Wednesday 30 June featuring a panel of expert speakers including MVEC’s A/Prof Nigel Crawford. The topic for the webinar is Primary care identification and management of thrombosis with thrombocytopenia syndrome (TTS) 并将涵盖：
- pathogenesis
- latest incidence rates in age groups
- incidence of different TTS clinical types
- presentation and identification
- GP management guidelines.
有关注册的更多信息和详细信息，请访问以下链接：
RACGP: Government announces new vaccine counselling MBS item number
Federal Health Minister Greg Hunt has announced the introduction of a newly-created MBS item in response to rising vaccine hesitancy related to widespread reporting the rare condition, thrombosis with thrombocytopenia syndrome, following receipt of the COVID-19 AstraZeneca vaccine. The new Medicare item, known as the Level B equivalent, will provide patients over 50 with a $38.75 rebate when receiving COVID vaccine counselling from their GP.
The introduction of this scheme will allow more time for GPs to address patient concerns and provide support in making informed decisions seen as crucial to boosting vaccination rates.
要了解更多信息，请点击以下链接：
RACGP: Government announces new vaccine counselling MBS item number
ATAGI 关于使用 COVID-19 疫苗阿斯利康的修订建议声明，2021 年 6 月 17 日
ATAGI has revised the recommendations for COVID-19 vaccination within Australia.
Due to a higher risk and severity of thrombosis with thrombycytopenia syndrome (TTS) related to the use of COVID-19 AstraZeneca, Comirnaty™ is now the preferred COVID-19 vaccine for individuals aged 16-59 years. Due to the risk of severe outcomes related to COVID-19 disease for individuals aged 60 years and over, the benefits of vaccination in preventing disease outweighs the risk of developing TTS.
Individuals aged less than 60 years who have received their first dose of COVID-19 AstraZeneca without any serious adverse events (eg. anaphylaxis or TTS) should continue to receive their second dose.
For more information please refer to the link below:
ATAGI 关于使用 COVID-19 疫苗阿斯利康的修订建议声明，2021 年 6 月 17 日
New immunisation reference page: COVID-19 mixed vaccine schedules
With the emergence of variant COVID-19 strains, global vaccine supply issues, and the need to rapidly immunise the population, a number of clinical trials are investigating the option of “mixed schedules”. Mixed schedules have been used previously in other vaccination strategies and involve the administration of different vaccine brands to complete a vaccine course.
Our new reference page explores the clinical trials underway which aim to determine the safety of mixed scheduling, the immunogenicity, as well as the recommendations for intervals between doses.
Due to a lack of available data, mixed vaccine schedules are not currently approved in Australia however are in use in Canada and across Europe.
要了解更多信息，请点击以下链接：
MVEC: COVID-19 mixed vaccine schedules
纽约时报：耗资数十亿美元的计划很快就会结束脊髓灰质炎
全球根除脊髓灰质炎行动宣布了一项 $51 亿美元的计划，到 2026 年在全球范围内根除脊髓灰质炎。2021 年 8 月，非洲国家宣布消灭野生脊髓灰质炎，阿富汗和巴基斯坦成为仅存的地方病国家。由于资金不足和缺乏政治承诺，以前在实现无脊髓灰质炎世界方面取得的成功有限。冠状病毒大流行增加了更多挑战，导致一些脊髓灰质炎疫苗接种计划停止。
新计划将侧重于两个关键目标：将脊髓灰质炎疫苗接种计划与其他医疗保健计划相结合，并重点关注免疫接种率长期较低的地区。该计划还确保疫苗供应并概述了提高疫苗接受度的沟通策略。除此之外，还引入了一种新的口服疫苗，并被认为可以最大限度地降低疫苗引起的脊髓灰质炎的风险。
根除脊髓灰质炎计划的一个关键重点是为难以到达的社区提供免疫接种，并培训年长的女性卫生工作者，她们更能成功地说服护理人员为孩子接种疫苗。为了恢复将根除脊髓灰质炎作为优先事项，即使在这些现金匮乏的国家面临竞争激烈的健康挑战，专家认为，旨在消灭脊髓灰质炎的计划也可用于帮助管理 COVID-19 和其他疾病。
要了解更多信息，请点击以下链接：
纽约时报：耗资数十亿美元的计划很快就会结束脊髓灰质炎